Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
17 September 2024 - 6:01AM
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage
biopharmaceutical company committed to bringing transformative
bifunctional therapies for patients with solid tumors, today
announced the closing of its initial public offering of 20,125,000
shares of its common stock at a public offering price of $18.00 per
share, which includes 2,625,000 shares issued upon the exercise in
full by the underwriters of their option to purchase additional
shares of common stock in the offering. Bicara Therapeutics’ shares
began trading on the Nasdaq Global Market on September 13, 2024
under the ticker symbol “BCAX.” All of the shares of common stock
were sold by Bicara Therapeutics.
Morgan Stanley, TD Cowen, Cantor and Stifel acted as joint
bookrunners for the offering.
The gross proceeds to Bicara Therapeutics from the initial
public offering, including full exercise of the underwriters’
option to purchase additional shares, before deducting underwriting
discounts and commissions and offering expenses payable by Bicara
Therapeutics, were approximately $362 million.
A registration statement relating to the shares sold in the
initial public offering has been filed with the Securities and
Exchange Commission and was declared effective on September 12,
2024. The offering was made only by means of a prospectus. A copy
of the final prospectus, may be obtained from: Morgan Stanley &
Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014, by telephone at (866) 718-1649, or by
email at prospectus@morganstanley.com; TD Securities (USA) LLC, 1
Vanderbilt Avenue, New York, New York 10017, by telephone at (855)
495-9846, or by email at TD.ECM_Prospectus@tdsecurities.com; Cantor
Fitzgerald & Co., Attention: Capital Markets, 110 East 59th
Street, 6th Floor, New York, New York 10022 or by email at
prospectus@cantor.com; or Stifel, Nicolaus & Company,
Incorporated, Attention: Prospectus Department, One Montgomery
Street, Suite 3700, San Francisco, CA 94104 by telephone at (415)
364-2720 or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical
company committed to bringing transformative bifunctional therapies
to patients with solid tumors. Bicara’s lead asset, ficerafusp
alfa, is a bifunctional antibody that combines two clinically
validated targets, an epidermal growth factor receptor (EGFR)
directed monoclonal antibody with a domain that binds to human
transforming growth factor beta (TGF-β). Through this
dual-targeting mechanism, ficerafusp alfa has the potential to
exert potent anti-tumor activity by simultaneously blocking both
cancer cell-intrinsic EGFR survival and proliferation, as well as
the immunosuppressive TGF-β signaling within the tumor
microenvironment. Ficerafusp alfa is initially being developed in
head and neck squamous cell carcinoma, where there remains a
significant unmet need.
Contacts
InvestorsRachel FrankIR@bicara.com
MediaDan Budwick1ABdan@1abmedia.com
Bicara Therapeutics (NASDAQ:BCAX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Bicara Therapeutics (NASDAQ:BCAX)
Historical Stock Chart
From Jan 2024 to Jan 2025